Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Artisan Mid Cap Fund Matt Kamm, Jason White, Jim Hamel, Angela Wu, Jay Warner | “Waters is a leading provider of liquid chromatography and mass spectrometry instruments for pharmaceutical and industrial applications. Its franchise position in pharmaceutical quality assurance testing drives strong recurring revenue (consumables and software to enable the instrument installed base). We expect the company to benefit from a rebound in commercial and late-stage clinical pharma demand, an instrument replacement cycle and growing exposure to biologic medicines. We added to the position after strong quarterly results, as we believe the share price did not reflect improving biologics momentum, emerging revenue synergies and favorable regulatory trends. BSD Analysis: Waters is a precision instruments company hiding behind a boring exterior — and that's exactly the appeal. Its chromatography and mass spectrometry tools are embedded in regulated workflows where switching is painful and risky. Demand is tied to pharma, biotech, and quality control, not hype cycles. Margins are consistently strong due to consumables and service revenue. Growth is steady, not spectacular, but incredibly reliable. R&D keeps the technology relevant without blowing up the cost base. Waters doesn't chase trends; it waits for customers who can't afford failure. This is life-sciences infrastructure with a long memory. Boring here is a feature.” | BULL | Q4 2025 Jan 15, 2026 | View Pitch |
Kovitz Core Equity Kovitz Investment Group Partners, LLC | “Waters is a leading manufacturer of analytical instruments, along with associated consumables and software, used to separate and identify chemical compounds, for customers in the biotech/pharma, materials, and food science end markets. Shares fell nearly 20% since Waters announced it was acquiring Becton-Dickinson's (BD's) Biosciences and Diagnostics business in mid-July. As owners of Becton-Dickinson, we believe the assets acquired by Waters are underappreciated in their own right and are a good strategic fit with Waters' existing business. BSD Analysis: Waters' acquisition of BD's diagnostics unit broadens its recurring revenue base and enhances product synergies. Its defensible position in high-margin analytical instruments, low government exposure, and strong balance sheet support long-term EPS compounding. Near-term integration risk is outweighed by strategic upside.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
The London Company SMID Cap Brian Campbell | “WAT underperformed on the announcement that it will acquire Becton Dickinson's Biosciences and Diagnostics divisions. While we take a skeptical view toward transformational M&A, we do see the strategic logic of the deal, and we have confidence in management's ability to execute on commercial improvements and cost synergies. We continue to have a favorable view of WAT's core business and the management team. BSD Analysis: The fund remains constructive on Waters despite M&A-related uncertainty. The acquisition broadens end-market exposure and long-term growth capacity. Solid margins, recurring revenue, and strong ROIC underpin resilience.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Impax Global Environmental Markets Fund Fotis Chatzimichalakis, Sanjeev Lakhani, Luciano Lilloy | “Waters (Health Care, Environmental Testing & Monitoring) moved lower during the quarter, driven by increasing attention on the US Administration's attempt to moderate drug pricing in the US. If successful, this could have a negative downstream effect on life science tools companies such as Waters. The stock also traded down on its Q1 earnings release. Whilst the results were solid, they were below elevated investor expectations. BSD Analysis: Waters is a premium player in analytical instruments, chromatography, and mass spectrometry, serving pharma, biotech, and advanced materials researchers. Its installed base is massive, generating sticky recurring revenue from consumables and services. While growth can ebb with biopharma funding cycles, Waters' position in regulatory workflows keeps demand fairly defensive. The company is modernizing its portfolio and improving software integration, which should enhance customer lock-in. Margins are strong due to premium pricing and high-value instruments. Waters may grow slower than some life-science peers, but it executes with discipline and stability. This is a steady picks-and-shovels name in scientific research.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
